IP Library Granted Patent US 10,597,738
Granted Patent B2
US 10,597,738 · App. 15/968,292 · Granted Mar 24, 2020

Compositions, methods and kits to detect herpes simplex virus nucleic acid

Inventors: Damon K. Getman (Poway, CA); Aparna Aiyer (San Diego, CA); Wendy Chen (Diamond Bar, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/705C12Q1/6865C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,738
App. No.
15/968,292
Granted
Mar 24, 2020
Kind
B2
Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (eg. HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claims (10)

1. An isolated nucleic acid comprising the sequence of SEQ ID Nos: 13, 14, 19, or 20 or the reverse complement thereof, or the RNA equivalent of any of these sequences, and a detectable label.

2. The isolated DNA or RNA sequence according to claim 1 , wherein said sequence is the reverse complement of SEQ ID Nos: 13, 14, 19, or 20.

3. The isolated nucleic acid sequence according to claim 1 , wherein the sequence is RNA.

4. The isolated nucleic acid sequence according to claim 1 , wherein the sequence is double stranded DNA.

5. The isolated nucleic acid sequence of claim 4 , wherein one end of a strand of the nucleic acid is joined to one end of another strand of the nucleic acid by an adapter.

6. The isolated nucleic acid sequence of claim 5 , wherein each end of a strand is joined to an end of another strand by adapters, thereby forming a circularized double stranded nucleic acid.

7. The isolated nucleic acid sequence of claim 1 , wherein the label is AE.

8. A method of detection HSV-1 or HSV-2 RNA within a sample, comprising separating HSV-1 or HSV-2 RNA from other sample components by attachment to a support, amplifying the HSV-1 or HSV-2 RNA by transcription mediated amplification, contacting amplification product resulting from the amplification with a nucleic acid according to claim 1 , wherein presence of a detectable signal from the label indicates presence of HSV-1 or HSV-2 RNA within the sample.

9. The method of claim 8 , wherein the attachment to the support is performed using a target capture system comprising a target-specific capture probe of HSV-1 or HSV-2.

10. The isolated nucleic acid of claim 1 comprising the sequence of SEQ ID Nos: 13, 14, 19, or 20.

Assignments (5)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 054089/0804 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; GEN-PROBE PRODESSE, INC.
Reel/Frame 075504/0575 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
SECURITY INTEREST Recorded Oct 19, 2018
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, INC.; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047272/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2018
From: GETMAN, DAMON K.; AIYER, APARNA; CHEN, WENDY
To: GEN-PROBE INCORPORATED
Reel/Frame 046607/0923 →